Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 7.12Kilitch Drugs (India) Ltd presents a picture of a rapidly expanding and highly profitable company with a very strong, debt-free financial structure. Its key strengths are exceptional growth in sales and profits, alongside excellent returns on investments. This indicates a healthy demand for its offerings and effective cost controls. However, the company faces significant operational challenges. It is very slow in collecting payments from its customers, which puts a strain on its available cash. While the company is financially stable due to its low debt, its day-to-day cash position appears tight. The future outlook is positive, driven by strong growth and profitability, but its success will also depend on how well it manages its cash flow and operational efficiency during its expansion phase.
Health Score : 7.12Kilitch Drugs (India) Ltd presents a picture of a rapidly expanding and highly profitable company with a very strong, debt-free financial structure. Its key strengths are exceptional growth in sales and profits, alongside excellent returns on investments. This indicates a healthy demand for its offerings and effective cost controls. However, the company faces significant operational challenges. It is very slow in collecting payments from its customers, which puts a strain on its available cash. While the company is financially stable due to its low debt, its day-to-day cash position appears tight. The future outlook is positive, driven by strong growth and profitability, but its success will also depend on how well it manages its cash flow and operational efficiency during its expansion phase.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
21.25
Industry Median
32.11
Small Cap Median
29.58
P/E RATIO
22.83
P/B RATIO
2.46
Industry Median
3.40
Small Cap Median
2.79
P/S RATIO
2.90
Industry Median
3.48
Small Cap Median
2.81
Others
PEG RATIO
0.00
EV/EBITDA RATIO
14.77
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹196.99 as on Jul 2, 2026.
Growth Score : 10.00The company is experiencing a period of exceptional and broad-based growth. It shows outstanding expansion across revenues, operating profits, and net income. Furthermore, its earnings per share and asset base are also increasing at a very strong pace. This indicates a highly successful business strategy, strong market demand, and effective execution. This robust growth profile is a key strength and points towards a positive future trajectory and increasing market presence.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 67.65 | 22.81 | 10 | 28.57 | 18.69 |
| Operating Profit Growth Rate | 100 | 80 | 33.33 | 33.33 | 15.62 |
| Earnings Per Share (EPS) Growth | 99.08 | 41.94 | 35.39 | 82.97 | 13.11 |
| Asset Growth Rate | 3.45 | 4.76 | 9.09 | 30.42 | 46.33 |
| Net Income Growth Rate | 50 | 33.33 | 75 | 78.57 | 20 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | ACCENTMIC | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 2 | KILITCH | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 3 | NGLFINE | 6.98 | 35.99 | Neutral | 73.00 | 67.39 | 48.00 |
| 4 | SAKAR | 6.89 | 64.59 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 5 | MEDICO | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 6 | KOPRAN | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 7 | SMSLIFE | 6.59 | 22.55 | Undervalued | 45.00 | 58.80 | 19.00 |
| 8 | INFINIUM | 6.42 | 31.32 | Neutral | 22.00 | 6.43 | 14.00 |
| 9 | MEDICAMEQ | 5.73 | 33.47 | Neutral | 20.00 | 6.94 | 10.00 |
| 10 | AAREYDRUGS | 5.73 | 60.35 | Neutral | 7.00 | 1.40 | 4.00 |
| 11 | ALBERTDAVD | 5.63 | -332.55 | Neutral | 5.00 | -2.62 | -1.00 |
| 12 | BPL | 5.46 | -28.70 | Neutral | -4.82 | -1.69 | -8.55 |
| 13 | ZIMLAB | 5.41 | 114.50 | Neutral | 30.00 | 1.11 | 6.00 |
| 14 | REMUS | 5.31 | 29.34 | Neutral | 57.00 | 20.97 | 46.00 |
| 15 | INDSWFTLAB | 4.95 | 68.00 | Neutral | 45.00 | 4.89 | 41.00 |
| 16 | VENUSREM | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 17 | LYKALABS | 4.77 | -26.63 | Neutral | -4.00 | -8.93 | -10.00 |
| 18 | WANBURY | 4.65 | 28.36 | Neutral | 88.00 | 18.93 | 43.00 |
| 19 | NECLIFE | 3.83 | -0.75 | Neutral | -59.00 | -2.95 | -293.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
No Stock Reports Available at This Moment.
No Stock News Available at This Moment.
Kilitch Drugs (India) Ltd is a Mumbai-based pharmaceutical company specializing in manufacturing and marketing a diverse portfolio of finished dosage forms, including sterile injectables, liquid orals, tablets, and capsules. It serves both domestic and international markets, with a strong focus on contract manufacturing and therapeutic segments like anti-infectives, anti-malarials, and anti-fungals.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Kilitch Drugs (India) Ltd's P/E ratio (TTM) is 21.25, compared to the industry median of 32.11 and large cap median of 29.58.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Kilitch Drugs (India) Ltd's P/B ratio is 2.46, compared to the industry median of 3.40 and large cap median of 2.79.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Kilitch Drugs (India) Ltd's P/S ratio is 2.90, compared to the industry median of 3.48 and large cap median of 2.81.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Kilitch Drugs (India) Ltd's PEG ratio is 0.95.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Kilitch Drugs (India) Ltd's EV/EBITDA ratio is 14.77.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Kilitch Drugs (India) Ltd's ROE is 10.71%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Kilitch Drugs (India) Ltd's ROA is 8.08%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Kilitch Drugs (India) Ltd's ROCE is 14%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Kilitch Drugs (India) Ltd's operating margin is 15.74%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Kilitch Drugs (India) Ltd's net margin is 12.77%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Kilitch Drugs (India) Ltd's current ratio is 1.48.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Kilitch Drugs (India) Ltd's debt-to-equity ratio is 0.20.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Kilitch Drugs (India) Ltd's interest coverage ratio is 7.50.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Kilitch Drugs (India) Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Kilitch Drugs (India) Ltd's EPS is 13.11.
(Source line: "Ratios as of 02 Jul 2026, based on last traded price of ₹196.99. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1977
Headquarters: Mumbai, Maharashtra
Core Offerings: Sterile Injectables, Liquid Orals, Tablets, Capsules, External Preparations
Stock Listing: NSE (KILITCH), BSE (524500)
Promoter: Mehta Family / Ashok Mehta Group
Kilitch Drugs (India) Ltd was incorporated in 1977, initially focusing on contract manufacturing of various pharmaceutical formulations. Over the decades, the company expanded its product portfolio, manufacturing capabilities, and market reach, establishing a significant presence in domestic and international markets, particularly for sterile injectables and specialized therapeutic areas. It has consistently invested in R&D and manufacturing infrastructure to meet global regulatory standards.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Products | 100% | Not explicitly segmented for revenue/EBITDA share |
Formulations Manufacturing: Produces a wide array of finished pharmaceutical dosage forms including injectables (vials, ampoules), liquid orals, tablets, and capsules across therapeutic segments like anti-infectives, anti-malarials, anti-fungals, and anti-inflammatories.
Contract Development & Manufacturing (CDMO): Offers contract manufacturing services to other pharmaceutical companies, leveraging its state-of-the-art facilities and regulatory compliance.
Domestic & International Markets: Caters to the Indian domestic market while also having a robust export presence in over 40 countries, primarily in Africa, Latin America, and Southeast Asia, adhering to various international regulatory guidelines.
Ashok Mehta - Chairman & Managing Director. Founder of the company, he provides strategic direction and drives the company's overall growth and vision. Manish Mehta - Whole-time Director. Son of the founder, he is actively involved in managing the company's operations, business development, and expansion initiatives.
Kilitch Healthcare India Limited (Wholly-owned subsidiary)
Kilitch Healthcare (East Africa) Limited (Step-down subsidiary)
Kilitch Healthcare (South Africa) (Pty) Limited (Step-down subsidiary)
Bonus Issue in 2023 (1:1 ratio); Bonus Issue in 2017 (1:1 ratio).
The Kilitch Drugs (India) Ltd share price today is ₹196.99 on NSE (KILITCH), as of 26 Aug 2026.
As of 02 Jul 2026, Kilitch Drugs (India) Ltd share price is ₹196.99, with previous close ₹196.99. Today's range is ₹196.99 to ₹196.99. The 52-week range is ₹196.99 to ₹196.99.
As of today, Kilitch Drugs (India) Ltd's market cap is ₹681.59 crore (Small Cap).
Kilitch Drugs (India) Ltd's current P/E ratio is 21.25, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 29.50.
Kilitch Drugs (India) Ltd's current P/B ratio is 2.46.
Kilitch Drugs (India) Ltd's current dividend yield is N/A. Last dividend of ₹1.00 per share was declared on 18-Aug-2023.
Kilitch Drugs (India) Ltd's EPS (TTM) is ₹13.11.
Kilitch Drugs (India) Ltd is a Mumbai-based pharmaceutical company specializing in manufacturing and marketing a diverse portfolio of finished dosage forms, including sterile injectables, liquid orals, tablets, and capsules. It serves both domestic and international markets, with a strong focus on contract manufacturing and therapeutic segments like anti-infectives, anti-malarials, and anti-fungals.
Kilitch Drugs (India) Ltd is promoted by Mehta Family / Ashok Mehta Group, holding 63.77% as of 02 Jul 2026.
Kilitch Drugs (India) Ltd is listed on NSE (KILITCH) and BSE (524500). Its next quarterly results are expected on August 2024.
Dividend Per Share (DPS)